Homogeneous Emphysema
Conditions
Keywords
emphysema, chronic obstructive pulmonary disease, lung volume reduction
Brief summary
The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in patients with homogeneous emphysema. Patients with upper lobe predominant emphysema initially screened for earlier Phase 2 studies but not enrolled before study enrollment closed are also eligible for participation.
Detailed description
Patients with emphysema currently have limited treatment choices. Many patients are treated with steroids and inhaled medications, which often provide little or no benefit. In recent years, lung volume reduction surgery has become an accepted therapy for advanced emphysema. Lung volume reduction surgery (LVRS) involves the removal of diseased portions of the lung in order to enable the remaining, healthier portions of the lung to function better. LVRS, although effective for many patients, is complicated and is accompanied by substantial morbidity and mortality risk. Aeris Therapeutics has developed the Biologic Lung Volume Reduction (BLVR) System which is intended to achieve lung volume reduction without surgery and its attendant risks. Patients are treated using a bronchoscope to direct treatment to the most damaged areas of the lung or in the case of homogeneous disease, areas that are less active as shown by the extent of regional blood flow. The treatment delivers a precisely proportioned proprietary mixture of drugs and biologics which, when combined at the treatment site, form a biodegradable hydrogel. The hydrogel acts to reduce lung volume by permanently collapsing and sealing the treated areas of the lung. This provides room within the chest to allow the remaining portions of the lung to function better. Aeris' BLVR development program has been granted Fast Track designation by the U.S. FDA, and is the subject of ongoing clinical trials designed to investigate the safety and efficacy of the BLVR System as a treatment for patients with advanced heterogeneous (upper lobe predominant) emphysema. Fast Track designation is reserved for drug and biologic development programs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.
Interventions
BIOLOGICALBiologic Lung Volume Reduction
20 mL Hydrogel
Sponsors
Aeris Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* clinical diagnosis of advanced homogeneous or upper lobe predominant emphysema demonstrated by CT scan * age \>/= 40 years * clinically significant dyspnea * failure of standard medical therapy (typically inhaled beta agonist & inhaled anticholinergic) to relieve symptoms * pulmonary function tests within protocol-specified ranges (post bronchodilator FEV1 \< 45% predicted & experiencing \< 30% or 300 mL improvement using bronchodilator; total lung capacity \> 110% predicted; residual volume \> 150% predicted) * 6 Minute Walk Distance \>/= 150 m
Exclusion criteria
* tobacco use within 4 months of initial visit or during study * body mass index \< 15 kg/m2 or\> 35 kg/m2 * clinically significant asthma, chronic bronchitis or bronchiectasis * allergy or sensitivity to procedural components * pregnant, lactating or unwilling to use birth control if required * prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant, endotracheal valve placement, airway stent placement or pleurodesis * comorbid condition that could adversely influence outcomes * inability to tolerate bronchoscopy under conscious sedation (or anesthesia) * history of renal infarction or renal failure lung perfusion scan indicating \> 20% of blood flow to either upper lung field or 30% total to both upper lung fields if homogeneous emphysema
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction in gas trapping | 12 weeks post treatment |
Secondary
| Measure | Time frame |
|---|---|
| improvement in expiratory flow | 12 weeks post treatment |
| improvement in vital capacity | 12 weeks post treatment |
| improvement in exercise capacity | 12 weeks post treatment |
| improvemnet in respiratory quality of life | 12 weeks post treatment |
| serious adverse events | through 2 years |
| improvement in dyspnea sysmptoms | 12 weeks post treatment |
Countries
United States
Outcome results
None listed